Optimal Antithrombotic Care for Patients with Acute Coronary Syndromes: Across the Continuum of Unstable Angina, NSTEMI, and STEMI

Credit Area For Credit: Register/Login     View Activity As Guest

Release Date: Aug 5, 2011          Expiration Date: Aug 5, 2012

This program has an associated Grand Rounds Click Here for information.

Program Description

Although dual antiplatelet therapy is well documented to reduce ischemic complications in patients with ACS, it is underused within the first 24 hours after hospitalization. This puts ACS patients at greater risk of atherothrombotic complications, including death. Newly approved and emerging antiplatelet agents promise to improve clinical outcomes of ACS patients. However, a gap exists between current practice in the acute management of ACS patients, and the level of physician understanding of new and emerging therapies that have the potential to improve patient outcomes. Physicians who treat ACS patients need to keep abreast of the latest clinical trial results and incorporate these insights into their clinical practices to provide optimum management of ACS patients.

Steering Committee

Deepak L. Bhatt, MD, MPH, FACC, FAHA, FSCAI
Chief of Cardiology, VA Boston Healthcare System
Director, Integrated Interventional Cardiovascular Program
Brigham and Women’s Hospital &
VA Boston Healthcare System
Associate Professor of Medicine, Harvard Medical School
Senior Investigator, TIMI Study Group
Boston, MA
Read Biography

Charles V. Pollack Jr., MA, MD, FACEP, FAAEM, FAHA
Professor and Chairman
Department of Emergency Medicine
Pennsylvania Hospital
University of Pennsylvania
Philadelphia, PA
Read Biography

Target Audience

This program is intended for internal medicine physicians, interventional cardiologists, emergency room physicians, cath lab personnel, hospitalists, pharmacists, and other clinicians who treat patients with ACS.

Educational Objectives

This program is designed to address the following IOM competencies: provide patient-centered care and employ evidence-based practice.

At the conclusion of this activity, participants should be able to demonstrate the ability to:

  • Adopt ischemic risk assessment stratification strategies to best evaluate patients with chest pain syndrome
  • Assess and stratify bleeding risk after antithrombotic treatment is initiated
  • Make treatment choices based on an understanding of the different mechanisms of action among antithrombotic agents, and on pertinent clinical trial results
  • Analyze pharmacologic and clinical trial results of newer antithrombotic agents to anticipate how they may impact standards of care of ACS patients


This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of Potomac Center for Medical Education and Rockpointe. Potomac Center for Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Designation Statement

The Potomac Center for Medical Education designates this educational activity for a maximum of 1.25 AMA PRA Category I credit(s)TM. Physicians should only claim credit commensurate with the extent of their participation in the activity.

     For information about the accreditation of this program, please email contact@potomacme.org

Disclosure Statement

Potomac Center for Medical Education (PCME) adheres to the policies and guidelines, including the Standards for Commercial Support, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous.

All persons in a position to control the content of a continuing medical education program sponsored by the Potomac Center for Medical Education are required to disclose any relevant financial relationships with any commercial interest to PCME as well as to learners. All conflicts are identified and resolved by PCME in accordance with the Standards for Commercial Support in advance of delivery of the activity to learners.

The content of this activity was vetted by an external medical reviewer to assure objectivity and that the activity is free of commercial bias.

The faculty reported the following relevant financial relationships that they or their spouse/partner have with commercial interests:

Deepak L. Bhatt, MD, MPH, FACC, FAHA, FSCAI: Principal Investigator: AstraZeneca, Bristol-Myers Squibb, Eisai, Sanofi-Aventis, The Medicines Company

Charles V. Pollack Jr., MA, MD, FACEP, FAAEM, FAHA: Consultant: Sanofi-Aventis, Bristol-Myers Squibb; Speaker: Bristol-Myers Squibb; Researcher: Sanofi-Aventis

Non-faculty content contributors and/or reviewers reported the following relevant financial relationships that they or their spouse/partner have with commercial interests:

Barry Watkins, PhD; Bradley Pine; Blair St. Amand; Jay Katz; Laurie Frueh, MD: Nothing to Disclose

FDA Disclosure

The contents of some CME/CE activities may contain discussions of non-approved or off-label uses of some agents mentioned. Please consult the prescribing information for full disclosure of approved uses.

System Requirements

In order to view this presentation, your computer must have audio capabilities (working speakers or headphones) and must have an Adobe Flash Player. The Adobe Flash Player can be downloaded here.

Instructions for Participants and Obtaining CME Credit

There is no fee for this activity. To receive credit, participants must take the pre-test, view this CME activity in its entirety, and then complete the post-test and evaluation. To complete the evaluation online, choose the best answer to each question. The estimated time for completion of this activity is 1.25 hours. To receive and print their certificates, participants must demonstrate mastery of the presented material via the post-test.

By clicking the View/Register Button you are agreeing that you have read and understood the information on this page.